#hepatocellular carcinoma

Checkpoint Immunotherapy Looks Promising for Operable Liver Cancer

In 2022, fatty liver disease accounted for nearly a quarter of all liver cancer cases on the transplant waiting list.

About 40% of people worldwide are not aware that viral hepatitis is a leading cause of liver cancer.

Human papillomavirus and hepatitis B vaccines lower the risk of developing cancer.

Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.

Results in cell and mouse studies may have implications for the development of a new class of anticancer drugs.

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

Experts predict that more than a million people could die from liver cancer worldwide in 2040.

October is Liver Cancer Awareness Month.

A study has identified a number of potential biomarkers that clinicians can use to predict how their patients will respond to treatment.

Imjudo plus Imfinzi improved overall survival compared with standard targeted therapy for hepatocellular carcinoma.

People with hepatocellular carcinoma had improved survival after the advent of direct-acting antiviral therapy.

However, people with liver cirrhosis remain at risk and should continue screening even after being cured.

New study supports U.S. guidelines for determining which people with liver cancer are eligible for a transplant.

Second- and third-generation individuals in Los Angeles had a 35% and 61% higher risk, respectively, than those born in Mexico.

The recent approval of several new medications has changed the treatment landscape.

“I’m glad to go to bat for the One Liver to Love initiative to encourage others to be proactive,” says Latino legend Bernie Williams.